The cut down in the lab in lab program now, towards the tail end of the pandemic, tells us that the lab in lab program is a failure, imo. If it was viable the board would be moving towards getting more funding from by approaching investors with evidence that the funding will not be wasted.
Instead we are getting restructuring costs for yet another shift in the business model, this time into online sales.
The failure of the lab in lab model now suggests that the product itself is not marketable. Clearly very few centres have managed to sell more than a couple of units each month.
OVN Price at posting:
18.0¢ Sentiment: None Disclosure: Held